People · Operator
Named in public records as an officer, director or promoter · active 2018–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Dracen Pharmaceuticals, Inc. | — | Biotechnology | Series A | $19.4M | $20.0M | 2018 |
Jonathan M. Leff at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jonathan M. Leff on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Thomas M. Estok | 1 | 3 |
| Asher M. Rubin | 1 | 2 |
| Robert M. Jackson | 1 | 2 |
| Drew M. Pardoll, M.D., Ph.D. | 1 | 1 |
| Dennis M. Bilski | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.